mhurhangee/ep-ind-claims huggingface dataset:
A solvent-free curable hot-melt silicone composition comprising an alkenyl group-containing organopolysiloxane having at least 2 alkenyl groups per molecule, wherein the alkenyl group-containing organopolysiloxane comprises a resinous organopolysiloxane containing alkenyl group and at least one (Ar2SiO2/2) unit; resinous organohydrogenpolysiloxane having at least 2 silicon-bonded hydrogen atoms per molecule, at 0.1 to 5% by mass relative to the total mass of the composition, an additive represented by average unit formula (C-1): (R 1 3 SiO 1/2) a (R 1 2 SiO 2/2) b (R 1 SiO 3/2) c (in the formula, R 1 is an identical or different alkyl group, aryl group, alkenyl group, aralkyl group, or epoxy group-containing organic group or alkoxy group, wherein at least one of R 1 is an alkenyl group, and at least one of R 1 is an epoxy group-containing organic group; and a, b, and c are numbers that satisfy 0≤a≤1.0, 0≤b≤1.0, 0≤c<0.9, respectively, and a + b + c = 1), hydrosilylation catalyst, and silica. an alkenyl group-containing organopolysiloxane having at least 2 alkenyl groups per molecule, wherein the alkenyl group-containing organopolysiloxane comprises a resinous organopolysiloxane containing alkenyl group and at least one (Ar2SiO2/2) unit; resinous organohydrogenpolysiloxane having at least 2 silicon-bonded hydrogen atoms per molecule, at 0.1 to 5% by mass relative to the total mass of the composition, an additive represented by average unit formula (C-1): (R 1 3 SiO 1/2) a (R 1 2 SiO 2/2) b (R 1 SiO 3/2) c (in the formula, R 1 is an identical or different alkyl group, aryl group, alkenyl group, aralkyl group, or epoxy group-containing organic group or alkoxy group, wherein at least one of R 1 is an alkenyl group, and at least one of R 1 is an epoxy group-containing organic group; and a, b, and c are numbers that satisfy 0≤a≤1.0, 0≤b≤1.0, 0≤c<0.9, respectively, and a + b + c = 1), hydrosilylation catalyst, and silica.
Extracorporeal blood treatment device having a display device, comprising: a projection surface or plate which is mounted to the extracorporeal blood treatment device and is configured to present a predetermined display content in a way visible to a user of the extracorporeal blood treatment device on a front side of the projection surface/plate; and a projection device which is mounted on the extracorporeal blood treatment device and is configured to project the predetermined display content from a rear side of the projection surface onto the projection surface, characterized in that a predetermined portion of the projection surface is provided for displaying at least one predetermined operating condition of the extracorporeal blood treatment device, in at least a first and a second operating condition, a predetermined first and/or second portion (36, 37) of the projection surface is controllably configured to display the first and second operating conditions in different colors, the projection surface is articulated by means of an articulating device, being a hinge-type joint arrangement, at a surface portion of the extracorporeal blood treatment device at a table-shaped molding or elevation, and/or is guided within a frame arrangement fixed at least in the height direction vis-à-vis the extracorporeal blood treatment device and is slidable within it, wherein the articulating device and/or the frame arrangement are overall configured to be movable in height such that the projection surface can be inserted at least partially into a recess of the extracorporeal blood treatment device. a projection surface or plate which is mounted to the extracorporeal blood treatment device and is configured to present a predetermined display content in a way visible to a user of the extracorporeal blood treatment device on a front side of the projection surface/plate; and a projection device which is mounted on the extracorporeal blood treatment device and is configured to project the predetermined display content from a rear side of the projection surface onto the projection surface, characterized in that a predetermined portion of the projection surface is provided for displaying at least one predetermined operating condition of the extracorporeal blood treatment device, in at least a first and a second operating condition, a predetermined first and/or second portion (36, 37) of the projection surface is controllably configured to display the first and second operating conditions in different colors, the projection surface is articulated by means of an articulating device, being a hinge-type joint arrangement, at a surface portion of the extracorporeal blood treatment device at a table-shaped molding or elevation, and/or is guided within a frame arrangement fixed at least in the height direction vis-à-vis the extracorporeal blood treatment device and is slidable within it, wherein the articulating device and/or the frame arrangement are overall configured to be movable in height such that the projection surface can be inserted at least partially into a recess of the extracorporeal blood treatment device.
Household refrigeration appliance having a receiver space for food, which is defined by walls of an internal container, having an extension device (7, 8) which is arranged on the internal container and which is able to be pushed into and pulled out of the receiver space relative to the internal container, and having a container (10, 14) for receiving food which is able to be removably positioned on the extension device (7, 8), wherein the extension device (7, 8) has a support cage for the container (10, 14) which, viewed in the width direction (x) of the household refrigeration appliance, has a base plate and retaining elements (12, 15) which are arranged thereon on opposing sides and separate from the base plate as lateral cage walls, wherein the retaining elements (12, 15) are configured as suspension elements for the releasable suspension in a non-destructive manner of the support cage on extension rails of the extension device (7, 8) which are separate from the support cage, characterised in that in each case the retaining elements (12, 15) have a supporting web (63, 64), the base plate being positioned thereon, and that the retaining elements (12, 15) on upper edges (68, 69) of one respective plate-shaped base part (70, 71) in each case have an outwardly oriented suspension web (72, 73) for suspending the retaining elements (12, 15) on the extension rails.
A method for transmitting uplink control information by a user equipment in a wireless communication system supporting carrier aggregation of a plurality of cells and operating in a time division duplex, TDD, the method comprising: receiving, by the user equipment, downlink signals on the plurality of cells, each of the downlink signals requiring a hybrid automatic repeat request acknowledgement, HARQ-ACK, response; and transmitting, by the user equipment, the uplink control information including per-cell HARQ-ACK bits for each cell in an uplink subframe via a physical uplink shared channel, PUSCH, wherein, when an uplink-downlink, UL-DL, configuration for performing the receiving and the transmitting is not a specific UL-DL configuration on each of the plurality of cells, the number of the per-cell HARQ-ACK bits for each cell is determined using a value of min(W, Mc), and wherein min(W, Mc) denotes a smallest value of W and Mc, W denotes a value indicated by 2-bit downlink assignment index, DAI, information included in downlink control information corresponding to the PUSCH, and Mc denotes the number of downlink subframes corresponding to the uplink subframe for each cell. receiving, by the user equipment, downlink signals on the plurality of cells, each of the downlink signals requiring a hybrid automatic repeat request acknowledgement, HARQ-ACK, response; and transmitting, by the user equipment, the uplink control information including per-cell HARQ-ACK bits for each cell in an uplink subframe via a physical uplink shared channel, PUSCH, wherein, when an uplink-downlink, UL-DL, configuration for performing the receiving and the transmitting is not a specific UL-DL configuration on each of the plurality of cells, the number of the per-cell HARQ-ACK bits for each cell is determined using a value of min(W, Mc), and wherein min(W, Mc) denotes a smallest value of W and Mc, W denotes a value indicated by 2-bit downlink assignment index, DAI, information included in downlink control information corresponding to the PUSCH, and Mc denotes the number of downlink subframes corresponding to the uplink subframe for each cell.
A compound of formula wherein R 1 is 1-methyl-1H-pyrazol-4-yl; R 2 is selected from hydrogen and fluoro; and R 3 is heterocyclyl 1, wherein heterocyclyl 1 is selected from piperazin-1-yl, morpholin-4-yl, 4-methoxypiperidin-1-yl, 4-hydroxypiperidin-1-yl, 3,5-dimethylpiperazin-1-yl, and 4-methyl-piperazin-1-yl; or a pharmaceutically acceptable salt thereof. R 1 is 1-methyl-1H-pyrazol-4-yl; R 2 is selected from hydrogen and fluoro; and R 3 is heterocyclyl 1, wherein heterocyclyl 1 is selected from piperazin-1-yl, morpholin-4-yl, 4-methoxypiperidin-1-yl, 4-hydroxypiperidin-1-yl, 3,5-dimethylpiperazin-1-yl, and 4-methyl-piperazin-1-yl; or a pharmaceutically acceptable salt thereof.
A method for determining a fuel quality of a fuel for a combustion engine, particularly for a diesel engine, wherein the fuel is conveyed from a low pressure fuel tank to a high-pressure volume (22a, 30), and injected into at least one cylinder of the combustion engine, wherein a control valve is provided for controlling directly or indirectly the amount of fuel injected into the at least one cylinder, wherein an actual value (S_24) of a timing signal of the control valve is compared to a reference value (S_ref) of the timing signal of the control valve and a fuel quality parameter is derived from a difference (ΔS) between the actual value (S_24) and the reference value (S_ref) of the timing signal of the control valve, characterized in that the timing signal of the control valve is refined with an actual value of a pumping period of a fuel pump conveying the fuel from the fuel tank to the combustion engine.
A method for enriching T cells and generating an engineered population of T cells, the method comprising: (a) performing a first selection, the first selection comprising enriching for either of CD57- or CD3+ T cells from a biological sample comprising primary human T cells, thereby generating an enriched T cell population; and (b) performing a second selection on the cells from the enriched T cell population, wherein: the first selection comprises enriching for CD57- T cells and the second selection comprises enriching for CD3+ T cells from the enriched population; or the first selection comprises enriching for CD3+ T cells and the second selection comprises removing CD57+ T cells from the enriched T cell population, wherein the method generates a depleted population that comprises fewer CD57+ T cells than the biological sample and is enriched for CD3+ T cells, and (c) introducing a heterologous polynucleotide encoding a recombinant receptor into a population of T cells obtained from the depleted population, thereby generating an engineered population of T cells. (a) performing a first selection, the first selection comprising enriching for either of CD57- or CD3+ T cells from a biological sample comprising primary human T cells, thereby generating an enriched T cell population; and (b) performing a second selection on the cells from the enriched T cell population, wherein: the first selection comprises enriching for CD57- T cells and the second selection comprises enriching for CD3+ T cells from the enriched population; or the first selection comprises enriching for CD3+ T cells and the second selection comprises removing CD57+ T cells from the enriched T cell population, wherein the method generates a depleted population that comprises fewer CD57+ T cells than the biological sample and is enriched for CD3+ T cells, and the first selection comprises enriching for CD57- T cells and the second selection comprises enriching for CD3+ T cells from the enriched population; or the first selection comprises enriching for CD3+ T cells and the second selection comprises removing CD57+ T cells from the enriched T cell population, wherein the method generates a depleted population that comprises fewer CD57+ T cells than the biological sample and is enriched for CD3+ T cells, and (c) introducing a heterologous polynucleotide encoding a recombinant receptor into a population of T cells obtained from the depleted population, thereby generating an engineered population of T cells.
A kit of parts, comprising: an article of footwear forming an elongated channel, the elongated channel having a first opening and a second opening; and a lighting apparatus including a base component the base component comprising: an elongated, flexible strip; a forward portion, a rearward portion, and an intermediate portion extending between the forward portion and the rearward portion, a removable portion attached to the forward portion; and a plurality of light-emitting devices being arranged throughout the intermediate portion; the base component configured to be extended through the first opening, through the elongated channel, and through the second opening, such that the removable portion extends outward from the second opening and the intermediate portion is disposed within the elongated channel; and the removable portion configured to be removed from the lighting apparatus following insertion of the intermediate portion into the elongated channel. an article of footwear forming an elongated channel, the elongated channel having a first opening and a second opening; and a lighting apparatus including a base component the base component comprising: an elongated, flexible strip; a forward portion, a rearward portion, and an intermediate portion extending between the forward portion and the rearward portion, a removable portion attached to the forward portion; and a plurality of light-emitting devices being arranged throughout the intermediate portion; the base component configured to be extended through the first opening, through the elongated channel, and through the second opening, such that the removable portion extends outward from the second opening and the intermediate portion is disposed within the elongated channel; and the removable portion configured to be removed from the lighting apparatus following insertion of the intermediate portion into the elongated channel. an elongated, flexible strip; a forward portion, a rearward portion, and an intermediate portion extending between the forward portion and the rearward portion, a removable portion attached to the forward portion; and a plurality of light-emitting devices being arranged throughout the intermediate portion; the base component configured to be extended through the first opening, through the elongated channel, and through the second opening, such that the removable portion extends outward from the second opening and the intermediate portion is disposed within the elongated channel; and the removable portion configured to be removed from the lighting apparatus following insertion of the intermediate portion into the elongated channel.
A rotary door check mechanism (120, 220) for use in a motor vehicle comprising a door check bar (121, 221) connected in use at a first end to one of part of a body structure (6, 106) of the motor vehicle and a structural part of a door (10, 105, 110) of the motor vehicle and having an end stop (22, 126) at a distal second end of the door check bar (121, 221) to the first end, a support housing (25, 125, 225) fastened in use to the other of the part of the body structure (6, 106) of the motor vehicle and the structural part of the door (10, 105, 110) of the motor vehicle and a door holding mechanism (130, 230), the door check mechanism (120, 220) having a rotary body member (131, 231) rotatably supported by the support housing (25, 125, 225) through which the door check bar (121, 221) extends characterized in that the rotary body member (131, 231) supports at least one spring loaded detent (132a, 132b, 232a, 232b), the or each spring loaded detent (132a, 132b, 232a, 232b) being engaged with a respective helical groove extending along the door check bar (121, 221) so as to provide a driving connection between the door check bar (121, 221) and the rotary body member (131, 231) to produce rotary motion of the rotary body member (131, 231) when there is relative movement between the rotary body member (131, 231) and the door check bar (121, 221), each helical groove including two or more check stops engageable by the co-operating spring loaded detent (132a, 132b, 232a, 232b) to define door check positions.
A Factor VIII composition for use in treating a patient by reconstituting a lyophilised Factor VIII composition in a volume of a diluent to prepare a reconstituted Factor VIII composition and administering the reconstituted Factor VIII composition to the patient, wherein the lyophilised Factor VIII composition is obtainable by lyophilizing a volume of a liquid Factor VIII composition formulated without adding albumin to said composition, wherein the liquid Factor VIII composition comprises the following formulation excipients in addition to Factor VIII: 4% to 10% of a bulking agent selected from the group consisting of mannitol, glycine and alanine; 1% to 4% of a stabilizing agent selected from the group consisting of sucrose, trehalose, raffinose, and arginine; 1 mM to 5 mM calcium salt; 100 mM to 300 mM NaCl; and a buffering agent for maintaining a pH of approximately between 6 and 8; and wherein the volume of the diluent is equal to or greater than the volume of the liquid Factor VIII composition. 4% to 10% of a bulking agent selected from the group consisting of mannitol, glycine and alanine; 1% to 4% of a stabilizing agent selected from the group consisting of sucrose, trehalose, raffinose, and arginine; 1 mM to 5 mM calcium salt; 100 mM to 300 mM NaCl; and a buffering agent for maintaining a pH of approximately between 6 and 8; and wherein the volume of the diluent is equal to or greater than the volume of the liquid Factor VIII composition.
A method for removing a viral contaminant from a preparation, being a cell culture medium or at least a component of a cell culture medium, comprising the step of: a) Subjecting said preparation to filtration for at least about 24 hours through a virus filter having an effective pore size of maximum 75 nm and a volumetric capacity of at least about 2000 L/m 2. a) Subjecting said preparation to filtration for at least about 24 hours through a virus filter having an effective pore size of maximum 75 nm and a volumetric capacity of at least about 2000 L/m 2.
A method of capturing a high dynamic range image on an image sensor, wherein the image sensor comprises a pixel array having a first plurality of pixel lines and a second plurality of pixel lines, wherein the first plurality of pixel lines and the second plurality of pixel lines are interlaced with each other, the method comprising: capturing, on the first plurality of pixel lines, a first image with a first exposure length,; capturing, on the second plurality of pixel lines, a plurality of images with a second exposure length, wherein the second exposure length is shorter than the first exposure length, wherein the plurality of images are captured sequentially during the capturing of the first image; combining the plurality of images with a second exposure length into a second image; and combining the first image and the second image to form a high dynamic range image. capturing, on the first plurality of pixel lines, a first image with a first exposure length,; capturing, on the second plurality of pixel lines, a plurality of images with a second exposure length, wherein the second exposure length is shorter than the first exposure length, wherein the plurality of images are captured sequentially during the capturing of the first image; combining the plurality of images with a second exposure length into a second image; and combining the first image and the second image to form a high dynamic range image.
Alkoxysilane-functionalized, allophanate-containing coating compositions comprising a) 10-99 wt% of at least one binder component from the reaction product of i) monourethanes i) containing alkoxysilane groups and of the formula 1 R n (OR 1) 3-n Si-R 2 -NH-(C=O)-OR 3 formula 1, where R n, R 1, R 2 and R 3 are each independently hydrocarbon radicals having 1-8 carbon atoms, which may be linear, branched or cyclic, or else may be integrated together to form a cyclic system, and n is 0-2, and ii) at least one diisocyanate ii), in a molar ratio of i) to ii) of from 3:1 to 1.5:1, preferably from 2.5:1 to 1.8:1, particularly preferably 2:1; b) 1-90 wt% of at least one binder component, preferably a hydroxyl-containing or amino-containing binder, c) 0-50 wt% of at least one aromatic, aliphatic or cycloaliphatic polyisocyanate having an NCO functionality of at least 2, preferably 2.8 to 6, d) 0-5 wt% of at least one catalyst, where components a)- d) add up to 100 wt%, e) optionally auxiliaries and/or additive, f) optionally solvents. a) 10-99 wt% of at least one binder component from the reaction product of i) monourethanes i) containing alkoxysilane groups and of the formula 1 R n (OR 1) 3-n Si-R 2 -NH-(C=O)-OR 3 formula 1, where R n, R 1, R 2 and R 3 are each independently hydrocarbon radicals having 1-8 carbon atoms, which may be linear, branched or cyclic, or else may be integrated together to form a cyclic system, and n is 0-2, and ii) at least one diisocyanate ii), in a molar ratio of i) to ii) of from 3:1 to 1.5:1, preferably from 2.5:1 to 1.8:1, particularly preferably 2:1; i) monourethanes i) containing alkoxysilane groups and of the formula 1 R n (OR 1) 3-n Si-R 2 -NH-(C=O)-OR 3 formula 1, where R n, R 1, R 2 and R 3 are each independently hydrocarbon radicals having 1-8 carbon atoms, which may be linear, branched or cyclic, or else may be integrated together to form a cyclic system, and n is 0-2, and ii) at least one diisocyanate ii), in a molar ratio of i) to ii) of from 3:1 to 1.5:1, preferably from 2.5:1 to 1.8:1, particularly preferably 2:1; b) 1-90 wt% of at least one binder component, preferably a hydroxyl-containing or amino-containing binder, c) 0-50 wt% of at least one aromatic, aliphatic or cycloaliphatic polyisocyanate having an NCO functionality of at least 2, preferably 2.8 to 6, d) 0-5 wt% of at least one catalyst, where components a)- d) add up to 100 wt%, e) optionally auxiliaries and/or additive, f) optionally solvents.